US-based biotechnology firm Neurocrine Biosciences has started a Phase IIb clinical trial (T-Force GOLD) of Ingrezza (valbenazine) for the treatment of children and adolescents with Tourette syndrome.

Ingrezza is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated as a capsule formulation for treating adults with tardive dyskinesia in the US.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Reportedly, the investigational candidate does not have significant binding affinity for VMAT1, dopaminergic, serotonergic, adrenergic, histaminergic or muscarinic receptors.

The multi-centre, randomised, double-blind, placebo-controlled, parallel group Phase IIb trial is designed to evaluate the safety, tolerability, efficacy and optimal dose of once-a-day Ingrezza.

Up to 120 subjects with moderate to severe disease will be administered with Ingrezza or placebo for 12 weeks, followed by two weeks off-drug period.

“We are committed to continuing studies of Ingrezza in patients with neurological disorders including paediatric patients with Tourette syndrome.”

Neurocrine Biosciences chief medical officer Christopher O’Brien said: “We are committed to continuing studies of Ingrezza in patients with neurological disorders including paediatric patients with Tourette syndrome.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We have gained valuable insights from our previous studies of Ingrezza in patients with Tourette syndrome and look forward to continuing to advance this programme to further assess Ingrezza as a potential treatment option for paediatric Tourette patients.”

The T-Force GOLD trial’s primary endpoint is change of the Yale Global Tic Severity Scale from baseline to end of week 12 between active and placebo arms.

During the trial, disease symptoms will be assessed using the Premonitory Urge for Tics and Clinical Global Impression Scales.

Neurocrine expects that the top-line results from the Phase IIb trial will be available late next year.